OJEMDA ™ (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson

CARY, N.C., April 26, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Day One Biopharmaceuticals, as a limited network specialty pharmacy for OJEMDATM (tovorafenib) for the treatment of pediatric low-grade glioma (pLGG). ...
Source: McKesson News - Category: Information Technology Source Type: news